< Zurück zu den aktuellen Neuigkeiten & Events

Veranstaltungen

IAM Pharma & Biotech IP Summit 2020 – London

Januar 2020

Veranstaltungsdatum: 28. Januar 2020

HGF is a gold sponsor at IAM Pharma & Biotech IP Summit on 28th January 2020 with Partner Douglas Drysdale and Patent Director Dr Emma Longland attending the event.

The life sciences are in a period of dramatic change and innovation with developments in new technologies challenging traditional IP strategies and business models. IAM’s Pharma and Biotech IP will bring together leading in-house practitioners and expert counsel to discuss next-generation strategies for protecting and exploiting cutting-edge innovation.

HGF Partner Douglas Drysdale will be attending and joining a panel to discuss Protecting the next generation of therapies:

A wave of cutting-edge technologies – from personalised medicines to gene and cell therapies – have become the focus of innovation in the life sciences, raising new challenges for IP professionals. An expert panel will shed light on:

  • The patentability questions raised by new technologies
  • How to gain the strongest possible protection for these technologies
  • Relevant international differences

HGF Patent Director Dr Emma Longland will also be attending.

Register here

Aktuelle Neuigkeiten

The Antibody Series #2 Definition via binding strength in antibody claims: when “binds strongly... but only minimally...” becomes a trap of lack of clarity

Introduction Defining an antibody by its binding strength is common practice in patent claims, but it can quickly become a pitfall under Article 84 EPC on clarity. In this second …

Weiterlesen
Event - 7. January 2026

HGF Brand & Design Conference 2026

Join us on 3rd February 2026 for HGF’s Brand & Design Conference, the must attend event for in-house legal teams, brand leaders, creatives, and innovators shaping the future of IP. …

Veranstaltungsdetails

Empowered, Not Replaced: The Risks and Rewards of Using AI Tools in Patent Prosecution

With the rapid rise of AI and extreme hype around generative AI tools in the workplace, patent firms around the world have had to seriously consider to what extent they …

Weiterlesen

EU Agrees on NGT Plant Regulation: What It Means for Patents and Licensing

The European Parliament and Council have reached a provisional agreement for plants developed using New Genomic Techniques (NGTs) – below we summarise the main points and set out the requirements …

Weiterlesen

When Retail Branding Meets Politics

(Inter IKEA Systems v Algemeen Vlaams Belang (Case C‑298/23) In November 2022, the Flemish political party Vlaams Belang presented its “IKEA-PLAN – Immigratie Kan Echt Anders” (“Immigration Really Can Be Different”). …

Weiterlesen

Büro geschlossen – Dezember 2025 / Januar 2026

HGF Büro geschlossen – Dezember 2025 / Januar 2026   UK Donnerstag, 25. und Freitag, 26. Dezember 2025 GESCHLOSSEN Donnerstag, 1. Januar 2026* GESCHLOSSEN * Freitag, 2. Januar 2026 – …

Weiterlesen

Oft kopiert, nie erreicht: Wann werden Alltagsgegenstände zum Gegenstand des Urheberrechts?

Die Grenze zwischen „reinen“ Kunstwerken und bloßen Gebrauchsgegenständen – Können ikonische, aber alltägliche Produkte urheberrechtlich geschützt werden? Die obige Frage wurde vom Generalanwalt in den verbundenen Rechtssachen C‑580/23 und C‑795/23 …

Weiterlesen

T 0883/23: Dosierungsansprüche und ihr Anspruch auf Priorität, wenn in der Prioritätsanmeldung nur das Protokoll der klinischen Studie offengelegt wurde

In einer kürzlich ergangenen Entscheidung der Beschwerdekammer (BoA) des EPA entschied die BoA, dass Ansprüche, die auf eine Kombination von pharmazeutischen Wirkstoffen (APIs) in bestimmten Dosen gerichtet sind, keinen Anspruch …

Weiterlesen
Alle Neuigkeiten anzeigen